Business Context and Reporting Period
Regentis Biomaterials Ltd., a foreign private issuer based in Israel, filed this Form 6-K on June 15, 2026, covering the month of June 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural filing regarding a registration statement and does not contain financial performance data.
Material Changes
The Company has determined not to pursue the public offering associated with Registration Statement No. 333-295510 on Form F-1. Consequently, the Company filed a request for the withdrawal of this Registration Statement, which became effective on June 15, 2026.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the cessation of the planned public offering. The primary unusual item is the voluntary withdrawal of the IPO registration.
Investor Verification Checklist
- Confirm the official withdrawal of Registration Statement No. 333-295510.
- Verify the reasons for discontinuing the public offering, as they are not detailed in this filing.
- Check for subsequent filings that may disclose the Company's current capitalization or alternative financing plans.